Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 140000
Corporate User License Price USD 6000
Corporate User License Price INR 420000
Site License Price USD 4000
Site License Price INR 280000
Request a Quote

Report Title

Bone Fracture-Pipeline Review, H2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Bone Fracture-Pipeline Review, H2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Bone Fracture-Pipeline Review, H2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Bone Fracture-Pipeline Review, H2 2017



Executive Summary

Bone Fracture-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture-Pipeline Review, H2 2017, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.

Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bone Fracture-Overview 6

Bone Fracture-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Bone Fracture-Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Bone Fracture-Companies Involved in Therapeutics Development 23

American Gene Technologies International Inc 23

BiologicsMD Inc 23

Biopharm GmbH 23

Bone Therapeutics SA 24

Cellmid Ltd 24

Chrysalis BioTherapeutics Inc 25

Entera Bio Ltd 25

Escape Therapeutics Inc 25

ethris GmbH 26

Kuros Biosciences AG 26

Laboratorios SALVAT SA 27

Novartis AG 27

Pluristem Therapeutics Inc 28

TissueGene Inc 28

Viking Therapeutics Inc 29

Bone Fracture-Drug Profiles 30

ALLOB-Drug Profile 30

bimagrumab-Drug Profile 34

BMD-1221-Drug Profile 37

cannabidiol-Drug Profile 38

Cell Therapy for Non-Union Fractures-Drug Profile 41

Cyndacel-M-Drug Profile 42

denosumab biosimilar-Drug Profile 44

dibotermin alfa biosimilar-Drug Profile 45

Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture-Drug Profile 46

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders-Drug Profile 47

Gene Therapy for Bone Fracture-Drug Profile 48

Gene Therapy for Bone Fracture-Drug Profile 49

Gene Therapy to Activate BMP2 and VEGF for Bone Fracture-Drug Profile 50

HCSVT-1001-Drug Profile 51

KAL-436-Drug Profile 52

KAL-439-Drug Profile 54

KUR-111-Drug Profile 55

KUR-113-Drug Profile 57

LWnt-3a-Drug Profile 59

Monoclonal Antibody to Inhibit Midkine for Bone Fractures-Drug Profile 60

Oligonucleotide to Activate BMP-2 for Bone Fracture-Drug Profile 61

OsteoStem-Drug Profile 62

PLX-PAD-Drug Profile 63

PREOB-Drug Profile 74

Recombinant Peptide to Agonize PTH1R for Bone Fracture-Drug Profile 77

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease-Drug Profile 78

rusalatide acetate-Drug Profile 80

S-008399-Drug Profile 84

Small Molecules for Metabolic and Musculoskeletal Disorders-Drug Profile 85

Small Molecules for Musculoskeletal and Metabolic Disorders-Drug Profile 86

SPI-86-Drug Profile 87

Synthetic Peptide for Osteoporosis and Bone Fracture-Drug Profile 88

TG-B-Drug Profile 89

VK-5211-Drug Profile 90

Bone Fracture-Dormant Projects 93

Bone Fracture-Discontinued Products 94

Bone Fracture-Product Development Milestones 95

Featured News & Press Releases 95

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Bone Fracture, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Bone Fracture, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Bone Fracture-Pipeline by American Gene Technologies International Inc, H2 2017

Bone Fracture-Pipeline by BiologicsMD Inc, H2 2017

Bone Fracture-Pipeline by Biopharm GmbH, H2 2017

Bone Fracture-Pipeline by Bone Therapeutics SA, H2 2017

Bone Fracture-Pipeline by Cellmid Ltd, H2 2017

Bone Fracture-Pipeline by Chrysalis BioTherapeutics Inc, H2 2017

Bone Fracture-Pipeline by Entera Bio Ltd, H2 2017

Bone Fracture-Pipeline by Escape Therapeutics Inc, H2 2017

Bone Fracture-Pipeline by ethris GmbH, H2 2017

Bone Fracture-Pipeline by Kuros Biosciences AG, H2 2017

Bone Fracture-Pipeline by Laboratorios SALVAT SA, H2 2017

Bone Fracture-Pipeline by Novartis AG, H2 2017

Bone Fracture-Pipeline by Pluristem Therapeutics Inc, H2 2017

Bone Fracture-Pipeline by TissueGene Inc, H2 2017

Bone Fracture-Pipeline by Viking Therapeutics Inc, H2 2017

Bone Fracture-Dormant Projects, H2 2017

Bone Fracture-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

American Gene Technologies International Inc

BiologicsMD Inc

Biopharm GmbH

Bone Therapeutics SA

Cellmid Ltd

Chrysalis BioTherapeutics Inc

Entera Bio Ltd

Escape Therapeutics Inc

ethris GmbH

Kuros Biosciences AG

Laboratorios SALVAT SA

Novartis AG

Pluristem Therapeutics Inc

TissueGene Inc

Viking Therapeutics Inc

Bone Fracture Therapeutic Products under Development, Key Players in Bone Fracture Therapeutics, Bone Fracture Pipeline Overview, Bone Fracture Pipeline, Bone Fracture Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person